Chymotrypsinogen

Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe

Retrieved on: 
Thursday, May 25, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, OTC Markets Group, CSCS, Skin, European Patent Office, Cancer, United States of Europe, Statista, Breast, Brain, Prostate, IP, Lung, EPO, EFPIA, PRP, Patient, Patent, BAS, European Federation of Pharmaceutical Industries and Associations, Chymotrypsinogen, Liechtenstein, Trypsinogen, Kidney, European Patent Convention, Liver, Growth, MEI, News, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCBD) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s intellectual property (IP) portfolio made important advancements in Europe.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCBD) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s intellectual property (IP) portfolio made important advancements in Europe.
  • The dosing patent, describing claims for the dosing regimen of the Company’s lead product candidate, PRP, has now been validated in 12 countries across Europe.
  • This is the third patent allowed, or granted to the Company in Europe, with further applications under examination by the EPO.
  • As a result of validating the dosing patent across Europe, the Company’s IP portfolio has grown to 76 patents either allowed, or granted in major jurisdictions around the world.

Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America

Retrieved on: 
Tuesday, May 23, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, Stem Cells, FDA, Health, OTC Markets Group, PPCB, Patent, Perseverance, CSCS, MB, Skin, Neoplasm, United States Patent and Trademark Office, Cancer, Breast, Brain, Prostate, IP, Lung, Bachelor of Medicine, Bachelor of Surgery, PRP, MD, Patient, BAS, Chymotrypsinogen, CIPO, Trypsinogen, Kidney, Canadian Intellectual Property Office, Growth, Liver, MEI, Death, News, Pharmaceutical industry, Medical imaging

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s intellectual property (IP) portfolio achieved significant milestones in North America.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s intellectual property (IP) portfolio achieved significant milestones in North America.
  • The foundation patent, covering composition claims for the Company’s lead product candidate, PRP, received a notice of allowance from the Canadian Intellectual Property Office (CIPO).
  • Propanc has an accepted application or achieved grant status for the foundation patent in over 30 different countries across North America, Europe, Asia, the Middle East and Japan.
  • “The milestones achieved for our intellectual property portfolio in North America are highly significant, as we now have patents in force in every jurisdiction selected by the Company for future commercialization of PRP,” said James Nathanielsz, BAS, MEI, Propanc’s Chief Executive Officer.

Propanc Biopharma Announces Reverse Stock Split

Retrieved on: 
Tuesday, May 23, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, OTC Markets Group, PPCB, Skin, OTC Bulletin Board, Breast, University, Brain, Prostate, Lung, PRP, Patient, Chymotrypsinogen, Trypsinogen, Kidney, Liver, CUSIP, Growth, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s board of directors (the “Board”) has approved a reverse stock split of its common stock at a ratio of 1 post-split share for every 1,000 pre-split shares.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s board of directors (the “Board”) has approved a reverse stock split of its common stock at a ratio of 1 post-split share for every 1,000 pre-split shares.
  • The reverse stock split was approved by the Board and the Company’s majority stockholder, representing the majority vote of the stockholders of the Company, on May 1, 2023.
  • On May 1, 2023, the Company filed a certificate of amendment to the Company’s certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effectuate the reverse stock split.
  • The reverse stock split does not affect the total number of shares of capital stock, including the common stock, that the Company is authorized to issue, or the par value of the common stock, which shall remain as set forth pursuant to the Company’s certificate of incorporation.

Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer

Retrieved on: 
Tuesday, March 28, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Immortalised cell line, OTC Markets Group, PPCB, Pancreatic cancer, University, TGF, MB, Skin, Neoplasm, Survival, Cell proliferation, Cancer, Breast, Brain, Prostate, Biomarker, Doctor of Philosophy, Lung, Bachelor of Medicine, Bachelor of Surgery, PRP, MD, Patient, Chymotrypsinogen, Trypsinogen, Kidney, Liver, Growth, Malignancy, Death, Tumor microenvironment, Medical imaging

TGF-β is a growth factor molecule involved in cell proliferation, migration and survival, and death that influences tumor growth in advanced forms of cancer.

Key Points: 
  • TGF-β is a growth factor molecule involved in cell proliferation, migration and survival, and death that influences tumor growth in advanced forms of cancer.
  • In addition, Mrs. Cutillas also analyzed the same pathway comparing (i) a pancreatic tumor cell line along with a chemoresistant pancreatic tumor cell line with (ii) the same line treated with PRP.
  • It was observed the TGF-β pathway, which is overexpressed in the chemoresistant cell line, decreased drastically when treated with PRP.
  • Mrs. Cutillas concluded that the results appear to confirm that PRP can suppress not only the tumor microenvironment, but also chemoresistant tumor cells, which also plays a key role in how a malignant tumor grows and spreads.

Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells

Retrieved on: 
Thursday, March 16, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Tumor microenvironment, Prostate, Lung, Kidney, Gene, Trypsinogen, MD, Pancreatic cancer, Brain, PPCB, MB, Cell, Liver, PRP, Patient, Bachelor of Medicine, Bachelor of Surgery, Growth, Skin, Drug resistance, Doctor of Philosophy, Chymotrypsinogen, II, University, OTC Markets Group, Real-time, Breast, Medical imaging

Laboratory studies by qPCR (quantitative polymerase chain reaction), along with western and immunofluorescence analyses, confirm downregulation of chemoresistant genes expression in chemoresistant tumor cells treated with PRP, compared with tumor cells and untreated chemoresistant tumor cells as experimental controls.

Key Points: 
  • Laboratory studies by qPCR (quantitative polymerase chain reaction), along with western and immunofluorescence analyses, confirm downregulation of chemoresistant genes expression in chemoresistant tumor cells treated with PRP, compared with tumor cells and untreated chemoresistant tumor cells as experimental controls.
  • Mrs. Cutillas believes the results are “fantastic” and corroborate her research into the effects of PRP as a chemosensitizing agent against pancreatic cancer, and the influence of PRP on the tumor microenvironment.
  • The work undertaken with our joint research partners confirms PRP effects the tumor microenvironment and suppresses chemoresistant genes in pancreatic tumor cells.
  • PRP is a unique approach because, rather than inhibiting a specific gene target, it re-educates these cells to overcome tumor resistance.

Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)

Retrieved on: 
Wednesday, January 11, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Congress, Radiation, Kidney, Prostate, Brain, OTC Markets Group, University, Neoplasm, PRP, Quality of life, POP1, Breast, Skin, MD, PAMM, Tumor microenvironment, Bachelor of Medicine, Bachelor of Surgery, Lung, Treatment, Trypsinogen, Chymotrypsinogen, Partnership, MB, PPCB, Growth, Patient, Pharmacology, TME, EORTC, Liver, Recurrence, III, European Organization for Quality, Pharmaceutical industry, Cancer, Research

Mrs. Toledo Cutillas commented that results and discussion on the novel approach was well received at the Congress in Florence, Italy.

Key Points: 
  • Mrs. Toledo Cutillas commented that results and discussion on the novel approach was well received at the Congress in Florence, Italy.
  • The EORTC research network consists of over 5,500 collaborators from all disciplines involved in cancer treatment and research in more than 930 institutions in 27 countries.
  • Its research spans the entire spectrum from translational and pre-clinical research to large, prospective, multi-center, phase III clinical trials that evaluate new cancer therapies.
  • Propanc is currently undertaking two joint research and collaboration projects with the Universities of Jáen and Granada.

Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén

Retrieved on: 
Thursday, December 15, 2022
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, B cell, Security (finance), Escape Room, Bachelor of Medicine, Bachelor of Surgery, Recurrence, CAFS, Fibroblast, Enzyme, PPCB, Tumor microenvironment, Lung, MD, Poster, Doctor of Philosophy, PRP, Skin, TME, Patient, Science, Master of Science, Research, Colorectal cancer, Accounting, Knowledge, Prostate, Liver, Neoplasm, Professor, FDA, Metastasis, Pancreas, Kidney, Growth, University, Breast, Chymotrypsinogen, Brain, OTC Markets Group, Trypsinogen, MB, Risk, Pharmaceutical industry, Medical imaging, Cancer

A copy of the publication can be accessed from the Companys website, via the following link: https://www.propanc.com/news-media/publications .

Key Points: 
  • A copy of the publication can be accessed from the Companys website, via the following link: https://www.propanc.com/news-media/publications .
  • PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection.
  • To view the Companys Mechanism of Action video on its anti-cancer lead product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video .
  • These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer

Retrieved on: 
Wednesday, November 30, 2022
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Growth, Colorectal cancer, Recurrence, TME, Science, OTC Markets Group, CAFS, Cancer-associated fibroblast, Lung, Journal, Kidney, Cell, PDAC, Immunosuppression, Mutation, MB, Pancreatic cancer, University, Cancer, Brain, Extracellular matrix, Patient, Enzyme, Trypsinogen, Tumor microenvironment, Pancreas, Liver, Prostate, Skin, Nature Communications, Accounting, Security (finance), Neoplasm, Prognosis, Metastasis, PRP, Fibroblast, Research, Bachelor of Medicine, Bachelor of Surgery, PPCB, Entrepreneurship, CAF, B cell, Chymotrypsinogen, Survival rate, Escape Room, FDA, Breast, Pharmaceutical industry, Medical imaging

Propanc Biopharma, Inc. (OTC Pink: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Chief Scientific Officer and Co-Founder, Dr. Julian Kenyon MD, MB, ChB, has recently come to the conclusion that PRP could become an effective chemosensitizer agent against pancreatic cancer.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Chief Scientific Officer and Co-Founder, Dr. Julian Kenyon MD, MB, ChB, has recently come to the conclusion that PRP could become an effective chemosensitizer agent against pancreatic cancer.
  • Pancreatic adenocarcinoma (PDAC) accounts for 80% of pancreatic cancers and has a 5-year survival rate of less than 8%.
  • This could have tremendous implications for PRP as a chemosensitizer agent with standard therapies to generate better clinical outcomes for PDAC patients.
  • Propanc Biopharma, Inc. (the Company) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers.

Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer

Retrieved on: 
Tuesday, November 15, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Lung, FDA, Enzyme, Bachelor of Medicine, Bachelor of Surgery, PPCB, Brain, Pancreas, Accounting, Cell adhesion, Liver, Phenotype, Entrepreneurship, MB, Prostate, PDA, World Journal of Gastroenterology, PRP, Drug resistance, Kidney, Science, Cancer, Neoplasm, Research, Recurrence, Security (finance), Immune system, OTC Markets Group, Tumor microenvironment, Trypsinogen, B cell, Pancreatic cancer, Growth, Diagnosis, Metastasis, Breast, Chymotrypsinogen, Patient, Pharmaceutical industry, Medical imaging, Vaccine

Propanc Biopharma, Inc. (OTC Pink: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Companys lead product candidate, PRP, could enhance the effects of novel therapies like immune checkpoint inhibitors that can have a role in pancreatic cancer treatment.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Companys lead product candidate, PRP, could enhance the effects of novel therapies like immune checkpoint inhibitors that can have a role in pancreatic cancer treatment.
  • One of the reasons for the poor effect of treatment is the ability of PDA to evade host immune surveillance.
  • To accomplish this, PRP targets specific pathways like TGF, critical for tumor development and prevention of immunorecognition by the bodys own immune system.
  • Immune checkpoint inhibitors have only recently been investigated for solid tumors like PDA and we are now only realizing the importance of the immune checkpoint inhibition in these cancers.

Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference

Retrieved on: 
Wednesday, October 26, 2022
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, Stem Cells, FDA, Health, U.S. Securities and Exchange Commission, Lung, Growth, Conference, Science, B cell, Patient, PPCB, Research, Security (finance), Enzyme, Entrepreneurship, Metastasis, Kidney, Cancer, Sidoti, Budget, Tumor microenvironment, Company, Prostate, Breast, Liver, Trypsinogen, Recurrence, Accounting, OTC Markets Group, Brain, Chymotrypsinogen, FDA, Pancreas, PRP, Pharmaceutical industry, Medical imaging

The Sidoti & Company Micro-Cap Investor Conference is a virtual event featuring dynamic, micro-cap companies interacting with a number of institutional investors from across the United States.

Key Points: 
  • The Sidoti & Company Micro-Cap Investor Conference is a virtual event featuring dynamic, micro-cap companies interacting with a number of institutional investors from across the United States.
  • Sidoti & Company is a provider of independent securities research focused on small and micro-cap companies and the institutions that invest in their securities.
  • Their investor conferences have emerged as a leading forum for interaction between issuers and investors in the small and micro-cap investment community.
  • These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.